Wells Fargo has raised its price target for Incyte (INCY) to $116 while maintaining an &#34;Overweight&#34; rating, reflecting an optimistic outlook after a 19.59% increase from the previous target. This follows a series of upward revisions by various analysts, suggesting strong market confidence in the biotechnology company. The average analyst target for INCY is $95.28, with an average brokerage recommendation of 2.3, indicating &#34;Outperform&#34; status.

因塞特醫療

<p>富國銀行已將因塞特醫療（Incyte，INCY）的目標股價上調至 116 美元，同時維持 “增持” 評級，反映出在目標上調 19.59% 後的樂觀前景。這一調整緊隨多位分析師的一系列上調修正，表明市場對這家生物技術公司的強勁信心。INCY 的平均分析師目標為 95.28 美元，平均券商推薦為 2.3，表明 “跑贏大盤” 的狀態</p>

因塞特醫療：富國銀行將目標價上調至 116 美元 | 因塞特醫療股票新聞